Halozyme Therapeutics develops proprietary enzymes and devices for various treatments. Products include Hylenex recombinant, rilpivirine, cabotegravir, ocrelizumab, XYOSTED, ATRS-1902, Herceptin, Mabthera SC, HYQVIA, DARZALEX, Epinephrine Injection, nivolumab+relatlimab, ANTI-TIM3, ARGX-117, atezolizumab, and others. The company provides treatments for breast cancer, chronic lymphocytic leukemia, primary immunodeficiency disorders, amyloidosis, smoldering myeloma, multiple myeloma, allergic reactions, solid tumors, and severe autoimmune diseases. Halozyme also offers products for adrenal crisis rescue and various other conditions. Founded in 1998, the company is headquartered in San Diego, California.
| Indicator | Value |
|---|---|
| PER | 16.7 |
| EV/EBITDA | 14.1 |
| Price/Free Cash Flow' | 15.8 |
| ROIC | 23.8% |
| Net Debt/EBITDA | 2.4 |